Agenus Is A Clinical Stage Biotechnology Company Based In Lexingtonmassachusettsdedicated To Developing Immuno Oncology Therapies For Cancer Treatmentfounded In 1994The Company Focuses On Harnessing The Immune System To Create Affordable And Effective Cancer Therapiesagenus Employs Combination Approaches That Include Antibody Therapeuticsadoptive Cell Therapiesand Adjuvants To Enhance Patient Access To Innovative Treatments The Company S Clinical Pipeline Features Botensilimaba Next Generation Ctla 4 Antibodywhich Is Being Studied In Combination With Balstilimaban Anti Pd 1 Antibodyfor Treating Cancers With Limited Optionssuch As Microsatellite Stable Colorectal Canceragenus Also Utilizes Proprietary Platforms For Antibody Discovery And Develops Allogeneic Invariant Natural Killer T Cell Therapies Through Its Subsidiarymink Therapeuticsadditionallyit Produces Saponin Based Vaccine Adjuvants Via Saponiqx To Boost Immune Responseswith A Commitment To Advancing Cancer Therapiesagenus Continues To Conduct Clinical Trials And Engage In Strategic Partnerships To Enhance Its Therapeutic Development Efforts
